The MarketWatch News Department was not involved in the creation of this content. Recent funding round, led by Hudson Bay Capital, fuels expanded capacity and commercialization of formulated ...

We now know what Bianca Censori’s BIO POP (THE ORIGIN) is, and furniture does play a key part after all. Thursday (Dec. 11), Censori launched the previously teased project in Seoul, revealing—as had ...

Formation Bio is inking a deal worth more than $600 million in biobucks for ex-China rights to a next-gen immunology asset from Lynk Pharmaceuticals. Lynk’s program will be developed by Formation’s ...

Naseem and Moe Mamtazi share why preserving Persian culture influences their winemaking choices, including long-held vintages and a commitment to natural, additive-free production at their Oregon ...

Securities and Exchange Commission filings indicate that Oxford Finance LLC acquired 1.62 million common shares, representing 16.5% ownership in the clinical-stage company. Oxford Finance, the ...

Curi Bio’s ribbon cutting in April 2025 for its new headquarters on Seattle’s waterfront. Elliot Fisher, co-founder and chief business officer, cuts the ribbon with a sword while CEO Nicholas Geisse ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. Down the line, Adagene could make up to $840 million in development and commercial ...

PRINCETON, N.J.--(BUSINESS WIRE)--NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration ...

An illustration of a protein created by Accipiter Bio that has two active sites, shown in light and darker green, that can simultaneously bind two targets. (Accipiter Bio Image) A Seattle biotech ...

This collaboration is a major step in BIO-key’s expansion across the Nordic region. The deal aims to deliver GDPR-compliant and scalable IAM technologies to strengthen identity protection and secure ...

Oct 14 (Reuters) - U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical (4502.T), opens new tab, deepening their ...

Cabaletta Bio offers pioneering CAR T-cell therapy for autoimmune diseases, with recent data showing promising efficacy and manageable safety. CABA's lead candidate, rese-cel, has demonstrated ...